Sandra Demaria

Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression.

Subverting misconceptions about radiation therapy.

Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.

Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Heavy Metal to Rock the Immune Infiltrate.

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers.

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Immune recognition of irradiated cancer cells.

The need for a network to establish and validate predictive biomarkers in cancer immunotherapy.

The Future of Radiobiology.

Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.

Trial watch: Immune checkpoint blockers for cancer therapy.

Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.

Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.

Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer.

SnapShot: CGAS-STING Signaling.

Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs.

Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect.

Cytosolic DNA Sensing in Organismal Tumor Control.

Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.

Radiotherapy induces responses of lung cancer to CTLA-4 blockade.

Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod.

Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system.

Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients.

The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018.

Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial.

CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection.

Exercise reduces immune suppression and breast cancer progression in a preclinical model.

The abscopal effect 67 years later: from a side story to center stage.

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.

Immunogenic Cell Death Driven by Radiation-Impact on the Tumor Microenvironment.

Radiotherapy Cooperates with IL15 to Induce Antitumor Immune Responses.

Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1.

Future of Radiation and Immunotherapy.

Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy).

Emerging technologies for local cancer treatment.

Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.

Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides.

Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control.

The role of radiotherapy in the age of immunotherapy.

Liver Metastasis Irradiation Can Restore Immunotherapeutic Responsiveness.

Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?

Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy).

LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells.

Something Old and Something New to Unleash the Power of Natural Killer Cells against Metastases.

Radiation therapy-induced remodeling of the tumor immune microenvironment.

Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021.

Quantitative assessment of mitophagy in irradiated cancer cells.

Immunologically relevant effects of radiation therapy on the tumor microenvironment.

Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors.

Pipeline to identify neoantigens exposed by radiation.

Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer.